uMedical
Medicines
Substances
Companies
Statistics
Menu
All medicines
Palsonify
Authorised
Human
Orphan medicine
Details
EMA number
EMEA/H/C/006636
ATC code
H01CB06
Authorisation
23 April 2026
Revision
1
EMA page
Therapeutic indication
Palsonify is indicated for the medical treatment of adult patients with acromegaly.
MeSH:
Acromegaly
Group:
Pituitary and hypothalamic hormones and analogues
Special characteristics
Additional monitoring
Active substances
paltusotine hydrochloride
Marketing Authorisation Holder
Crinetics Pharmaceuticals Europe GmbH
MAH
Timeline
Filter by authority:
EMA
Palsonify authorised
23 Apr 2026
authorised
regulatory
Palsonify | uMedical